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Bioinformatic analysisHuman bone marrow-derived stromal (skeletal) stem cells (BM-hMSC) are being employed in an increasing
number of clinical trials for tissue regeneration. A limiting factor for their clinical use is the inability to obtain suf-
ﬁcient cell numbers. Human embryonic stem cells (hESC) can provide an unlimited source of clinical grade cells
for therapy.Wehave generatedMSC-like cells fromhESC (called here hESC-stromal) that exhibit surfacemarkers
and differentiate to osteoblasts and adipocytes, similar to BM-hMSC. In the present study, we used microarray
analysis to compare the molecular phenotype of hESC-stromal and immortalised BM-hMSC cells (hMSC-TERT).
Of the 7379 genes expressed above baseline, only 9.3% of genes were differentially expressed between undiffer-
entiated hESC-stromal and BM-hMSC. Following ex vivo osteoblast induction, 665 and 695 genes exhibited
≥2-fold change (FC) in hESC-stromal and BM-hMSC, respectively with 172 genes common to both cell types.
Functional annotation of signiﬁcantly changing genes revealed similarities in gene ontology between the two
cell types. Interestingly, genes in categories of cell adhesion/motility and epithelial–mesenchymal transition
(EMT) were highly enriched in hESC-stromal whereas genes associated with cell cycle processes were enriched
in hMSC-TERT. This data suggests that while hESC-stromal cells exhibit a similar molecular phenotype to hMSC-
TERT, differences exist that can be explained by ontological differences between these two cell types. hESC-
stromal cells can thus be considered as a possible alternative candidate cells for hMSC, to be employed in regen-
erative medicine protocols.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Human bone marrow stromal stem cells (BM-hMSC) are adult,
multipotent stem cells present within the non-haematopoietic com-
partment of the bone marrow. BM-hMSC are capable of differentiating
into mesoderm-type cells e.g. osteoblasts, adipocytes (Abdallah and
Kassem, 2012), and chondrocytes (Puetzer et al., 2010, review) under
appropriate ex vivo conditions, and can form heterotopic bone and
bone marrow organ in vivo (Abdallah et al., 2005). hMSC are being in-
troduced for regenerative therapy in a number of clinical conditions in-
cluding repair of bone (Quarto et al., 2001) and cartilage defectsy Laboratory (KMEB), Odense
C, Denmark.
).
. This is an open access article under(Wakitani et al., 2002). In addition, the BM-hMSC secrete a large num-
ber of factors that exert anti-inﬂammatory and immunemodulatory ef-
fects and thus BM-hMSC have been used in phase I/II clinical trials of
tissue regeneration following cerebral haemorrhage (Heile et al.,
2009) and in graft-versus-host disease (GvHD) (Le Blanc et al., 2010).
One of the limiting factors forwider use of hMSC in therapy is the inabil-
ity to obtain a sufﬁcient number of cells needed for clinical applications.
This is due to the small number of hMSC recovered from bone marrow
aspirates and their limited proliferative potential during ex vivo expan-
sion (Stenderup et al., 2003).
Human embryonic stem cells (hESC) are pluripotent stem cells
(PSC) that can bemaintained ex vivo in a self-renewing state and there-
fore represent an unlimited source for generating differentiated cells for
regenerative therapies (Volarevic et al., 2011). Signiﬁcant progress has
beenmade in designing and validating efﬁcient differentiation protocolsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(Abdallah et al., 2011; Irion et al., 2008). Additionally, new technologies
allowing the expansion of pluripotent stem cells in bioreactors, without
enzymatic interventions,will allow a large number of PSC to be generated
prior to differentiation and transplantation (Chen et al., 2014). While the
most interesting application of hESC-derived differentiated cells is as a
universal off-the-shelf product for allogenic use in cell therapy, further re-
search about the in vivo functions of hESC-derived differentiated cells
need to be conducted both in animal models and in humans.
However, concerns have been raised regarding the ability of the
ex vivo differentiation of hESC to induce a differentiatedphenotype sim-
ilar to that observed in tissue-speciﬁc cells (Cahan andDaley, 2013). The
phenotype of hESC-derived differentiated cells have traditionally been
described based on a limited number of in vitro expressed lineage spe-
ciﬁc markers (D'Amour et al., 2005; Hay et al., 2008; Kroon et al., 2008).
Side-by-side comparisons of hESC-derived differentiated cells and bona
ﬁde tissue resident differentiated cells have rarely been conducted
(Irion et al., 2008). Four published reports have previously compared
mesodermal lineage differentiation of hESCwith tissue speciﬁc/resident
cells. Raynaud et al. investigated cardiomyocytes derived from hESC in
comparison with bone marrow mesenchymal cells (Raynaud et al.,
2013); Barbet et al., Bigdeli et al. and Barberi et al. all based their com-
parison of mesenchymal-like (MSC-L) cells, derived from hESC, and
bone marrow derived cells at baseline only (Barbet et al., 2011; Bigdeli
et al., 2010; Barberi et al., 2005). Interestingly, Barbet et al. demonstrat-
ed that MSC-like cells derived from hESC clustered closer with
BM-hMSC as compared to MSC-like derivatives with hESC (Barbet
et al., 2011). Thus, data examining differences between MSC-like cells
and BM-hMSC during osteoblastic induction are absent.
The availability of large-scale methods for gene proﬁling, such as
DNAmicroarrays, offers an opportunity to deﬁne the “molecular pheno-
type” of ex vivo cultured cells. Additionally, data mining using bioinfor-
matic tools can provide a functional understanding of pathways and
processes enriched in differentiated cell lineages and allow comparisons
between different cell populations (Klimanskaya et al., 2004; Larsen
et al., 2010; Lu et al., 2007; Marei et al., 2011).
We have developed an ex vivo culture method to isolate, propagate
and differentiate stromal cells obtained from hESC (termed here hESC-
stromal) into osteoblastic and adipocytic cells (Harkness et al., 2011).
At a cellular level, hESC-stromal exhibited comparable cluster of differ-
entiation (CD) surface markers, and differentiated to the osteoblastic
and adipocytic lineages using the same differentiation protocol
employed in hMSC-TERT (Harkness et al., 2011). In the present study,
we employed DNA microarrays to compare the molecular phenotype
of hESC-stromal to a bona ﬁde bone marrow-derived, immortalised,
hMSC. In addition, an in depth analysis of the differentiated phenotype
of hESC derived MSC-like cells has been obtained. Our results demon-
strate that these two cell populations are closely related at both the
cellular and molecular levels.
2. Methods
2.1. Cell culture
hESC-stromal cells were derived as previously described (Harkness
et al., 2011). Brieﬂy, stromal ﬁbroblast-like cells were isolated from an
in house Odense3 embryonic stem cell line (Harkness et al., 2011),
grownunder feeder free conditions in the presence ofmouse embryonic
ﬁbroblast (MEF) conditioned media, and cultured on hyaluronic acid-
coated culture plates (100 μg/ml; HA; Calbiochem-Merck, Darmstadt,
Germany) (Harkness et al., 2011). These cells were termed hESC-
stromal cells and were routinely cultured in high glucose DMEM
(Invitrogen, Taastrup, Denmark) with 10% FBS (PAA, Pasching,
Austria). As a model for BM-hMSC, we employed hMSC-TERT
(Simonsen et al., 2002) that exhibit a stable cellular andmolecular phe-
notype comparable to that of primary BM-hMSC (Al-Nbaheen et al.,2013). hMSC-TERT were routinely cultured in MEM (Invitrogen) with
10% FBS (PAA, Pasching, Austria).
Ex vivo osteoblast (OB) differentiation was performed using osteo-
blast induction medium containing β-Glycerophosphate (10 mM;
Calbiochem-Merck), L-ascorbic acid-2-phosphate (50 μg/ml; Sigma-
Aldrich, Brøndby, Denmark), dexamethasone (100 nM hESC-stromal,
10 nM hMSC-TERT; Sigma-Aldrich) and calcitriol (1,25 hydroxy-
Vitamin D3; 10nM). For samples collected for microarray analysis
media were changed every 2 days until day 6 for hESC-stromal (n = 3
independent experiments, at passages 6 and 7) or day 7 for hMSC-
TERT (n = 1 experiment, passage 48). Data for validation of array
gene expression was generated from 6 independent experiments and
plotted using the SEM (Fig. 4); data for initial comparison of hESC-
stromal and hMSC-TERT undifferentiated and undergoing OB induction
were calculated from3 independent experiments (Fig. 1). The OB differ-
entiated cells are termed: hESC-stromal-OB and hMSC-TERT-OB.
2.2. Alkaline phosphatase (ALP) activity measurements
ALP activity was quantiﬁed as previously described (Qiu et al., 2010)
using a 1 mg/ml solution of P-nitrophenylphosphate (Sigma-Aldrich,
Brøndby, Denmark) in 50 mM NaHCO3 with 1 mM MgCL2, pH 9.6, at
37 °C for 20 min. Activity was stopped using 3 M NaOH, absorbance of
each reaction (λmax = 405 nm) was measured using a FLUOstar
Omega plate reader (BMG Laboratories, Ramcon A/S, Birkerod,
Denmark) and ALP activity was normalised to cell number (n= 3 inde-
pendent experiments, 6 wells/experiment). Cell number was deter-
mined using a CellTiter-Blue Cell Viability assay, according to the
manufacturer's instructions (Promega, Nacka, Sweden). A two-tailed,
paired T-Test statistical analysis was used to establish if signiﬁcant
differences could be determined between the normalised ALP activity
of hESC-stromal-OB and hMSC-TERT-OB at 6 days of induction.
2.3. RNA isolation and real-time quantitative RT-PCR
Total RNA was isolated using TRIzol (Invitrogen) as previously re-
ported (Harkness et al., 2011) and cDNA was generated using a
revertAid H minus ﬁrst strand cDNA synthesis kit (Fermentas, St.
Leon-Rot, Germany) according to the manufacturer's instructions. RT-
PCR was performed on an ABI Step one PCR machine (Applied
Biosystems-Life Technologies, Carlsbad, CA, USA). Datawere normalised
to the geometric mean of the reference genes (β-Actin, B2M, HPRT,
UBC1) and analysed using a comparative Ct method where Δ-CT is the
difference between the CT values of the target and the geometric
mean of the reference genes. Primer sequences (Supplementary
Table 1) were designed using Primer-BLAST.
2.4. Illumina® bead chip microarray
Following RNA extraction, samples were puriﬁed using a GenElute
mammalian total RNA miniprep kit (Sigma-Aldrich; according to the
manufacturer's instructions). Five hundred nanograms of total RNA
per samplewere used for biotin-labelled cRNAproduction using a linear
ampliﬁcation kit (Ambion). Hybridizations, washing, Cy3-streptavidin
staining, and scanning were performed on the Illumina BeadStation
500 platform (Illumina®) according to the manufacturer's instruction.
cRNA samples were hybridised onto Illumina® human-8 BeadChips
version 3. All basic gene expression data analyses were carried out
using the BeadStudio® software 3.0. Raw data were background-
subtracted, normalised using the “rank invariant” algorithm and then
ﬁltered for signiﬁcant expression on the basis of negative control
beads. To demonstrate the relationship between the different samples,
hierarchical clustering was performed using the Illumina BeadStudio®
software. Correlation was used as the distance measure, and clustering
was performed with the average linkage method.
Fig. 1. Comparison of undifferentiated and in vitro osteoblast (OB) differentiated hESC-stromal and hMSC-TERT. (A) Gene expression of osteoblast lineage markers in hESC-stromal-OB■
and hMSC-TERT-OB (n = 3 independent experiments) and ALP activity normalised for cell number in hESC-stromal-OB and hMSC-TERT-OB (n = 3 independent experiments;
*p b 0.05); (B) Hierarchical clustering of cell samples following Illumina bead array.
34 L. Harkness et al. / Bone Reports 3 (2015) 32–392.5. Functional gene enrichment analysis
Data analysis for functional enrichment was performed using the Da-
tabase for Annotation, Visualization and Integrated Discovery (DAVID)
(Huang et al., 2008, 2009). Genes were selected for comparison if they
had a detection threshold p value b 0.01. Under OB induction, genes
that had a fold change (FC) of ≤−2 or ≥2 compared to the corresponding
controlwere employed in the analysis. Fold change fromundifferentiated
hESC-stromal over hMSC-TERT, hMSC-TERT over hESC-stromal and fold
change of OB induced/non induced for each cell line were analysed
using DAVID. Data from DAVID was plotted using the one tail Fisherexact probability value calculated by DAVID. MetaCore® v6.14 was
used to perform pathway enrichment analysis on genes signiﬁcantly
expressed (p b 0.01). Gene Ontology (GO) ossiﬁcation data were
downloaded from the GO database (http://www.geneontology.org/
GO.downloads.ontology.shtml). Ossiﬁcation genes, relative to undifferen-
tiated cells, differentially regulated during OB differentiationwere identi-
ﬁed (N2 FC or b−2 FC) in either hMSC-TERT-OB (n=17), hESC-stromal-
OB (n = 15) or in both hESC-stromal-OB and hMSC-TERT-OB (n = 11).
Studies published here did not require ethical approval further to
that published in the original derivation articles (Simonsen et al.,
2002; Harkness et al., 2010).
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3.1. Cellular phenotype
Cultured hESC-stromal and hMSC-TERT exhibited a ﬁbroblast-like
morphology at baseline and cuboidal morphology following ex vivoFig. 2.GO functional enrichment of hMSC-TERT and hESC-stromal cells over 2 FC (detection thre
hMSC-TERT show an increased annotation to developmental genes suggesting an increased cap
differentiatedhMSC-TERT/hESC-stromal demonstrate an increasedGOBP annotation to cell cycl
osteogenic differentiation unique to hESC-stromal-OB (n = 493); (D) GO functional enrichmeOB differentiation, respectively (data not shown). Both hESC-stromal
and hMSC-TERT responded to OB induction by upregulation of OB
marker genes: RUNX2, ALPL, COL1A1, BGLAP and SPP1 as well as ALP ac-
tivity (Fig. 1A). Both cell types formed heterotopic bone and bone mar-
row organ when implanted subcutaneously in immune deﬁcient mice
as previously reported (Harkness et al., 2011).shold p ≤ 0.01). (A)GObiological process categories of undifferentiated hESC-stromal cells/
acity for multi-lineage differentiation as compared to hMSC-TERT; (B) in comparison un-
e/mitosis categories; (C) GO functional enrichment of genes up and down regulatedduring
nt of up and down regulated genes unique to hMSC-TERT-OB (n = 523).
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vs. hMSC-TERT cells at baseline
Microarray analysis identiﬁed 7379 expressed genes (a gene was
considered to be expressed if the p-value of detection threshold is
≤0.01). Gene lists, used for GO BP and MetaCore® analyses as well as
comparison with GO database, were established by the following
criteria: undifferentiated genes regulated ≥2 FC of hESC-stromal/
hMSC-TERT with a detection p-value of ≤0.01; OB induced gene lists
were established for each cell line of OB induced/undifferentiated
≥2 FC with a detection p-value of ≤0.01. Hierarchical clustering demon-
strated a close relationship between undifferentiated hESC-stromal and
hMSC-TERT (Fig. 1B). The majority of genes demonstrated similar ex-
pression levels in both cell types with 9.3% of total expressed genes dif-
ferentially regulated (353 genes differentially up-regulated (FC ≥ 2) and
334 down-regulated (FC ≤ −2)) between the two cell lines. Functional
enrichment analysis for gene ontology (GO) biological processes (BP)
revealed, in hESC-stromal the highest enrichment scores in categories
of cell adhesion, mesodermal tissue developmental and cell motion
(Fig. 2A). In comparison, GO BP categories for cell division, response to
steroid hormone stimulus and positive regulation of apoptosis were
highly enriched in hMSC-TERT (Fig. 2B). An overview demonstrating
the distribution of genes (non-induced and OB induced) is shown in
the Venn diagrams in Supplementary Fig. 1A–D.
3.3. Comparison of molecular phenotype of hESC-stromal-OB vs.
hMSC-TERT-OB
Prior to selecting a time point during OB induction for microarray
analysis, hMSC-TERT and hESC-stromal, undergoing differentiation in-
duction, were compared using ALP activity and ALP gene expression
as a measure for osteoblast lineage differentiation. From these prelimi-
nary experiments d6 of hESC-stromal-OB and d7 of hMSC-TERT-OB
were selected as being the most comparable time points (data not
shown). In order to detect whether hESC-stromal and hMSC-TERT em-
ploy similar biological processes during ex vivo OB differentiation, we
compared hESC-stromal-OB and hMSC-TERT-OB utilising the following
four bio-informatic approaches.
First, osteoblast differentiation regulated genes were compared
between hESC-stromal and hMSC-TERT. Comparison of fold induction
(OB induced/undifferentiated) identiﬁed a comparable number of
genes both up and down regulated: 695 genes differentially regulated
(FC ≤ −2 or ≥2) in hMSC-TERT-OB and 665 genes in hESC-stromal-
OB. Among these, 172 genes (≈30%) were common to both cell types
following differentiation suggesting a common OB differentiation
program. Employing the DAVID tool for GO functional annotation of
BP, the highest enriched GO categories of these 172 genes included
mitosis, response to estradiol stimulus, insulin receptor signalling and
regulation of apoptosis (Supplementary Fig. 1E). In addition, the top
10 enriched GO categories for each cell type exhibited similarities e.g.
cell adhesion, angiogenesis, cytoskeletal organisation, response to hor-
mone stimulus and regulation of apoptosis (Fig. 2C and D). Conversely,
differences in GO categories were also observed. GO categories for
epithelial-to-mesenchymal (EMT) transition and cell morphogenesis
were unique for hESC-stromal-OB (Fig. 2C) whereas hMSC-TERT-OB
(Fig. 2D) were enriched in GO BP categories for cell cycle processes, mi-
totic processes and response to oxygen levels. Data lists detailing genes
annotated to the top 10 categories are presented in Supplementary
Table 2.
Second, we examined the separate annotations for genes that were
up- or down-regulated during OB differentiation in the two cell types.
hESC-stromal-OB demonstrated 231 genes and hMSC-TERT showed
335 genes that were up-regulated ≥2 FC during OB differentiation, and
among these 91 genes were common between the two cell types
(Supplementary Fig. 2). CommonGO categorieswere present e.g. prolif-
eration, response to hormone stimulus, regulation of apoptosis andregulation of cell adhesion. For genes down-regulated during OB differ-
entiation, 262 genes and 188 genes were found in hESC-stromal-OB
(Supplementary Fig. 3B) and hMSC-TERT-OB (Supplementary Fig. 3C),
respectively. Among these 81 genes were common between the two
cell types (Supplementary Fig. 3A) andwere enriched for GO categories:
mitosis and regulation of phosphorylation. The list of differentially up-
regulated or down-regulated genes in hESC-stromal-OB and hMSC-
TERT-OB are given in Supplementary Table 2.
Third, to test for the presence of a common “osteoblastic differentia-
tion signature” we curated an ‘ossiﬁcation’ GO dataset that identiﬁed
293 genes. Of these 293 genes, we found that 135 did not pass the
p-value detection threshold of ≤0.01 in either hESC-stromal-OB or
hMSC-TERT-OB. Of those genes that were expressed (p ≤ 0.01), 115
(73%) were expressed equally in both cell types, 25 (16%) genes were
uniquely expressed in hESC-stromal-OB and 18 (11%) genes uniquely
expressed in hMSC-TERT-OB (Supplementary Table 3).
Finally, we compared pathways enriched in hESC-stromal-OB and
hMSC-TERT-OB using MetaCore®. All expressed genes (detection p
value ≤ 0.01) in hMSC-TERT-OB and hESC-stromal-OB were employed.
The top 10 enriched pathways for hESC-stromal-OB and hMSC-TERT-OB
are shown in Fig. 3A and B, respectively. While common genetic path-
ways for both cell types included EMT and CSF signalling, their function
may differ. For example, hESC-stromal-OB demonstrated enrichment
for GM-CSF with a role in formation and release of inﬂammatory
cytokines whereas hMSC-TERT-OB was enriched in G-CSF with a role
in formation and release of granulocytes from bone marrow. In addi-
tion, both cell types demonstrated enrichment of the EMT pathway
through induction of TGFB signalling. Interestingly, hMSC-TERT-OB
demonstrated additional EMT pathway induced via MAPK and SMAD
signalling.
3.4. Validation of microarray data of hESC-stromal-OB and hMSC-TERT-OB
We chose 24 genes (FC ≤−2 or ≥2) that were found among the core
“ossiﬁcation” gene category for validating the microarray data using
real-time qRT-PCR (Fig. 4A–C). We included genes present in both
hESC-stromal-OB and hMSC-TERT-OB: CLEC3B, SRGN, IFITM1, PTN,
MN1, EXT1, CBS and IGFBP5, genes expressed uniquely in hESC-stromal
OB: DCN, COMP,MGP, P2RX7, SOX9, GLI2, PTGS2, IL6 or genes expressed
uniquely in hMSC-TERT-OB: TGBF3, TGBF2, PRKD1, CEBPB, ID1, ECM1,
GJA1,MMP2. As seen in Fig. 4A–C, qRT-PCR revealed a close correlation
of qRT-PCR measurements with those from DNA microarray data.
4. Discussion
In the presentmanuscript, we have compared themolecular pheno-
type of hMSC either derived from hESC or from bone marrow. While
there were some quantitative differences between the gene expression
and cellular responses, the two cell populations exhibited a high degree
of homology in relation to undifferentiated gene expression and qualita-
tive responses to OB differentiation induction. In addition, we identiﬁed
a common molecular signature and common core of genes and genetic
pathways that are employed by both cell types during in vitro OB
differentiation.
We used an immortalised cell line (hMSC-TERT) to compare with
hESC-stromal cells undifferentiated and under osteoblastic induction.
The hMSC-TERT cell line has been extensively characterised by our
group and has been demonstrated as a good predictivemodel for the bi-
ological behaviour of primary hMSC (Abdallah et al., 2005; Simonsen
et al., 2002). In addition, publications from other groups comparing
immortalised versus primary cells have also demonstrated retention
of basic cell characteristics (Boerma et al., 2006; Ouellette et al., 2000).
However, the expression of ectopic hTERT, and thus immortalisation,
is indicative that genes associated with cell cycle will be up-regulated
in comparison with primary cell lines. Thus, over-representation of
cell cycle categories in undifferentiated hMSC-TERT biological processes
Fig. 3. Enrichment analysis (MetaCore®) for unique and common pathways:
(A) pathways unique to hESC-stromal-OB; (B) pathways unique to hMSC-TERT-OB. Both
annotations demonstrate categories involved in EMT and TGFβ pathways suggesting
these are important to both cell types during differentiation.
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observed in non-induced hMSC-TERTwould be associatedwithmitosis,
however, while cell cycle genes were overrepresented, the majority of
the upregulated genes, annotated to mitosis, were between 2–3 FC
with only 3 genes demonstrating N3 FC upregulation when compared
to hESC-stromal (INCEP, CCNF, NEK2). These 3 genes were not found
within the top 50 hMSC-TERT genes which were differentially annotat-
ed in hESC-stromal. Functional clustering of the top 50 genes demon-
strated enrichment in categories: response to hormone stimulus and
skeletal system development. In comparison functional clustering of
the top 50 genes in hESC-stromal revealed enrichment for categories
of: smooth muscle proliferation and muscle organ development. This
suggests that these differences reﬂect differences of the ontology ofthe two cell types (adult versus embryonic) rather than immortalisation
caused by overexpression of hTERT in hMSC-TERT.
Data analysis determined that 90.3% of genes expressedwere similar
betweenundifferentiated hESC-stromal and hMSC-TERT. Our data, thus,
corroborates previously published reports comparing the molecular
phenotype of hESC-derived MSC-like cells and bone marrow-derived
hMSC (Raynaud et al., 2013; Barbet et al., 2011; Bigdeli et al., 2010;
Barberi et al., 2007). The authors demonstrated a close relationship be-
tween hESC-MSC-like cells and BM-hMSC employing principal compo-
nent analysis (PCA) and hierarchical clustering (Raynaud et al., 2013).
Barbet et al. identiﬁed differentially expressed genes utilising a Taqman
low-density array and reported that hESC-MSC clustered more closely
with BM-hMSC than with undifferentiated hESC (Barbet et al., 2011).
Barberi et al. utilised affymetrix oligonucleotide arrays on a CD73+
sorted population derived from hESC and compared these with
BM-hMSC (Barberi et al., 2005). Similar to our data the authors found
enrichment for genes associated with vascular development and
inﬂammatory response/wound healing. Finally, Bigdeli et al. (2010) re-
ported similarities in the enrichment of osteoblastic genes in undiffer-
entiated hESC-MSC and BM-MSC.
Other studies have examined themolecular phenotype of osteoblas-
tic cells differentiated from hESC i.e. hESC-MSC-OB as compared with
hiPSC-MSC-OB derived from induced pluripotent stem cells (iPSC)
(de Peppo et al., 2013) and demonstrated the ability of both cell types
to undergo in vitro osteoblastic differentiation. Global DNA microarray
analysis of hESC-MSC andhiPSC-MSC demonstrated similarities and dif-
ferences in both undifferentiated cells and in cells undergoing OB differ-
entiation. However, the limitation of these studies is the absence of
comparisonwith bonaﬁde osteoblastic cell populations e.g. osteoblastic
cells derived from BM-hMSC as we did in our current study. Our com-
parisonwith aGeneOntology (GO) derived osteogenic gene set demon-
strated that 73% of osteogenic genes found in hESC-stromal-OB and
hMSC-TERT-OB were similar. Within this common list, 11 genes were
regulated over 2 FC (p ≤ 0.01) of which only 1 gene (STC1)was differen-
tially regulated. In addition, of the 172 genes in the OB-induced cells
(FC ≤ −2 or ≥2; p ≤ 0.01) which were commonly expressed in both
cell types, 86% of the genes were similarly expressed. Analysis of
genes which were differentially regulated during OB induction
(FC ≤ −2 or ≥2; p ≤ 0.01) in hMSC-TERT-OB (n = 523) and in hESC-
stromal-OB (n = 493), showed that the majority (96.7% hMSC-TERT-
OB; 97% hESC-stromal-OB) did not demonstrate annotations for GO os-
siﬁcation. Data presented here therefore demonstrates a common set of
genes for OB induction shared between hESC-stromal and hMSC-TERT.
The large gene sets not exhibiting osteogenic annotation demonstrates
that osteogenesis involves an activation of a complex network of
genes related to basal biological processes.
A large number of genes in both hESC-stromal-OB and hMSC-TERT-
OB were annotated as related to epithelial-to-mesenchymal transition
(EMT). EMT is a mechanism for generation of primary mesenchyme
during embryogenesis (Kalluri andWeinberg, 2009) and is orchestrated
through Wnt signalling (Kalluri and Weinberg, 2009; Ullmann et al.,
2008). Among the 130 genes regulated during EMT (Groger et al.,
2012), 68 genes were present in hESC-stromal and 65 genes in hMSC-
TERT. Our study corroborates ﬁndings from previous studies reporting
that development of MSC-like cells in hESC cultures was mediated
through EMT as evidenced by differential regulation of E-cadherin and
N-cadherin (Ullmann et al., 2007), expression of EMT-associated
genes (Hwang et al., 2008) and ﬂow cytometric analysis of E-Cadherin
(Boyd et al., 2009).
We observed that the differentiated progeny of hESC, hESC-stromal
cells, did not express pluripotent markers e.g. POU5F1, SOX2, NANOG,
DNMT3B,GABRB3, and TDGF1 suggesting the loss of pluripotency andpro-
viding strong evidence that the hESC-derived differentiated cells will not
form teratomas or tumourswhen implanted in vivo. In support of this, tu-
mour formation was absent when hESC-stromal were subcutaneously
implanted in immune compromised mice (Harkness et al., 2011).
Fig. 4. Validation of microarray data by RT-PCR (n = 6 independent experiments): (A) genes common to hESC-stromal-OB (array—grey bar; PCR—black bar) and hMSC-TERT-OB
(array—grey bar; PCR—white bar) up or down regulated over 2 FC (p ≤ 0.01); (B) OB genes unique to hESC-stromal-OB; (C) OB genes unique to hMSC-TERT-OB. Data is presented as
fold change.
38 L. Harkness et al. / Bone Reports 3 (2015) 32–39Our data demonstrate similarities in the molecular phenotype
of undifferentiated and OB differentiated hESC-stromal cells
when compared with hMSC encouraging the use of hESC-stromal
cells as an alternative source of hMSC for regenerative medicine
protocols.
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